INmune Bio Inc. Common stock (INMB)
Stock · NASDAQ · Health Care
$2.33as of 8/28/2026
Price chart
Open in TradingViewActive signals
No technical signal is currently active for this symbol.
Support level
$1.26
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Fundamentals
- Market cap
- $50.78M
- P/E (trailing)
- —
- P/E (forward)
- —
- EPS (trailing)
- —
- Dividend yield
- —
- Beta
- —
- Avg. volume
- —
How INmune Bio Inc. Common stock Makes Money
Where the revenue actually goes — FY2024 annual results
Source: 10-K filed Mar 27, 2025 · via SEC EDGAR / Finnhub
INmune Bio Inc. Common stock Competitors
Chosen by industry and closest market cap.
- INMBINmune Bio Inc. Common stock$2.33▼ 2.92%Market cap $50.78MP/E —
- OKYOOKYO Pharma Limited Ordinary Shares$1.67▲ 7.74%Market cap $51.94MP/E —$1.34$3.2
- TILInstil Bio Inc. Common Stock$7.58▼ 3.56%Market cap $49.37MP/E —$5.67$33.83
- ATYRaTyr Pharma Inc. Common Stock$0.5361▼ 3.41%Market cap $49.22MP/E —
- EXOZeXoZymes Inc. Common Stock$7.17▼ 0.10%Market cap $47.57MP/E —$4.35$18.4
- INKTMiNK Therapeutics Inc. Common Stock$11.43▼ 2.16%Market cap $54.80MP/E —$8.48$16.98
- MGXMetagenomi Therapeutics Inc. Common Stock$1.2▼ 0.83%Market cap $46.68MP/E —
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| INMB INmune Bio Inc. Common stock | $50.78M | — | $2.33 | ▼ 2.92% | |
| OKYO OKYO Pharma Limited Ordinary Shares | $51.94M | — | $1.67 | ▲ 7.74% | $1.34$3.2 |
| TIL Instil Bio Inc. Common Stock | $49.37M | — | $7.58 | ▼ 3.56% | $5.67$33.83 |
| ATYR aTyr Pharma Inc. Common Stock | $49.22M | — | $0.5361 | ▼ 3.41% | |
| EXOZ eXoZymes Inc. Common Stock | $47.57M | — | $7.17 | ▼ 0.10% | $4.35$18.4 |
| INKT MiNK Therapeutics Inc. Common Stock | $54.80M | — | $11.43 | ▼ 2.16% | $8.48$16.98 |
| MGX Metagenomi Therapeutics Inc. Common Stock | $46.68M | — | $1.2 | ▼ 0.83% |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- INmune Bio Inc. (INMB) Q2 2026 Earnings Call TranscriptSeekingAlpha · 8/7/2026
- INmune Bio (NASDAQ:INMB) Beats Q2 Loss Estimates but Shares Tumble on Business UpdateChartMill · 8/6/2026
- INmune Bio Receives R&D Rebates of Approximately $4.6 MillionYahoo · 7/31/2026
- INmune Bio Inc. to Report Second Quarter 2026 Financial Results and Provide Corporate Update on Thursday, August 6thYahoo · 7/31/2026
Insider Activity
Insider Actions →Acquired
31.0K
Disposed
31.0K
- Juda Scott · July 2, 2026 · X14.8K @ $0.125
- Juda Scott · July 2, 2026 · Option Exercise14.8K @ $1.4
- Lowdell Mark William · July 2, 2026 · X7.2K @ $0.125
- Lowdell Mark William · July 2, 2026 · Option Exercise7.2K @ $1.4
- Moss David J · July 2, 2026 · X9.0K @ $0.125
- Moss David J · July 2, 2026 · Option Exercise9.0K @ $1.4
Institutional Ownership
March 31, 2026
- Total shares held
- 5.16M
- Total value held
- $5.83M
- Institutional holders
- 78
Top holders this quarter
- Unknown1.19M
- Unknown687.0K
- Unknown495.0K
- Unknown290.9K
- Unknown270.3K
- Unknown253.3K
- Unknown243.2K
- Unknown231.6K
- Unknown203.2K
- Unknown184.2K
See the full, filterable feed with live charts on the MarketWall dashboard.